ThomasA.HensingMDMS

Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Associate Chief Quality Officer, NorthShore University HealthSystem, Clinical Associate Professor of Medicine, University of Chicago Medicine

Join to view full profile

Dr. Hensing is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hensing's full profile

Already have an account?

Office
2650 Ridge Ave
Div. Of Hematology-Oncology
Evanston, IL 60201
Phone+1 888-909-5222

Fax+1 847-570-2336
Is this information wrong?

Education & Training

Northwestern UniversityMS, Healthcare Quality and Patient Safety, 2015 - 2017
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 1997 - 1999
University of North Carolina HospitalsResidency, Internal Medicine, 1994 - 1997
University of Maryland School of MedicineClass of 1994

Certifications & Licensure

IL State Medical License 2003 - 2026
NC State Medical License 1996 - 2003
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Super Doctor SuperDoctors.com

Clinical Trials

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Germline mutations in high penetrance genes are associated with worse clinical outcomes in patients with non-small cell lung cancer.
Seth B Krantz, Kanwal Zeeshan, Kristine M Kuchta, Thomas A Hensing, Kathy A Mangold, S Lilly Zheng, Jianfeng Xu> ;JTCVS Open. 2022 Dec 1
2 citations
Safe Transitions and Congregate Living in the Age of COVID-19: A Retrospective Cohort Study.
Christopher A Boyle, Urmila Ravichandran, Valerie Hankamp, Nadim M. Ilbawi, Coleen Conway-Svec, Diane Shifley, Thomas A. Hensing, Susan Kim, Lakshmi Halasyamani> ;Journal of Hospital Medicine. 2021 Aug 18
Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients W...
Thomas A. Hensing, Xiaofei Wang, Thomas E. Stinchcombe, Junheng Gao, Michael V. Knopp, Mark A. Watson, Arkadiusz Z. Dudek, Stephen L. Graziano, Jyoti D. Patel, Bryan A...> ;JTO Clinical and Research Reports. 2021 Aug 1
14 citations
Docetaxel, Oxaliplatin, and 5‐Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long‐Term Follo...
Ari Rosenberg, Alfred Rademaker, Howard S. Hochster, Theresa Ryan, Thomas A. Hensing, Veena Shankaran, Lisa Baddi, Devalingam Mahalingam, Mary F. Mulcahy, Al B. Benson> ;The Oncologist. 2019 Aug 1
15 citations
A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer
Nancy Lan Guo, Afshin Dowlati, Rebecca Raese, Chunlin Dong, Guoan Chen, David G. Beer, Justine Shaffer, Salvi Singh, Ujala Bokhary, Lin Liu, John A. Howington, Thomas ...> ;Ebiomedicine. 2018 Jun 1
21 citations
Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
Shalin Shah, Kevin Wood, Brian W. Labadie, Brian Won, Ryan J. Brisson, Theodore Karrison, Thomas A. Hensing, Mark Kozloff, Riyue Bao, Jyoti D. Patel, Jason J. Luke> ;Oncotarget. 2018 Jan 12
1 citations
PS01.63: Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non-Small Cell Lung Cancer (NSCLC): Topic: Medical Oncology.
Shah, S., Wood, K., Brisson, R., Karrison, T., Hensing, T. A., Luke, J. J., Patel, J. D.> ;Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Dec 15
KRAS in Non-Small-Cell Lung Cancer-Reply.
Kevin Wood, Thomas A. Hensing, Ravi Salgia> ;JAMA Oncology. 2016 Oct 1
7 citations
Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
Nicholas P. Campbell, Thomas A. Hensing, Mihir K. Bhayani, Arif Shaikh, Bruce Brockstein> ;Expert Review of Anticancer Therapy. 2016 Jul 11
117 citations
Prognostic and Predictive Value in KRAS in Non–Small-Cell Lung Cancer: A Review
Kevin Wood, Thomas A. Hensing, Raeva Malik, Ravi Salgia> ;JAMA Oncology. 2016 Jun 1
95 citations
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization
Siraj M. Ali, Thomas A. Hensing, Alexa B. Schrock, Justin M. Allen, Eric M. Sanford, Kyle Gowen, Atul Kulkarni, Jie He, James Suh, Doron Lipson, Julia A. Elvin, Roman ...> ;The Oncologist. 2016 Jun 1
2 citations
The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative.
Brian Won, George B. Carey, Yi-Hung Carol Tan, Ujala Bokhary, Michelle Itkonen, Kyle Szeto, James A. Wallace, Nicholas P. Campbell, Thomas A. Hensing, Ravi Salgia> ;Cureus. 2016 Mar 16
24 citations
Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute...
Janani Vigneswaran, Yi-Hung Carol Tan, Septimiu Murgu, Brian Won, Kathryn Alexa Patton, Victoria M. Villaflor, Philip C. Hoffman, Thomas A. Hensing, D. Kyle Hogarth, R...> ;Oncotarget. 2016 Feb 26
12 citations
Promotion of self-management for post treatment cancer survivors: evaluation of a risk-adapted visit.
Carol A. Rosenberg, Carol Flanagan, Bruce Brockstein, Jennifer Obel, Leon Harold Dragon, Douglas E. Merkel, Elaine Lee Wade, Teresa M. Law, Janardan D. Khandekar, Thom...> ;Journal of Cancer Survivorship. 2016 Feb 1
94 citations
Lung cancer—a fractal viewpoint
Frances E. Lennon, Gianguido C. Cianci, Nicole A. Cipriani, Thomas A. Hensing, Hannah J. Zhang, Chin-Tu Chen, Septimiu Murgu, Everett E. Vokes, Michael W. Vannier, Rav...> ;Nature Reviews. Clinical Oncology. 2015 Nov 1
100 citations
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
Daniel Morgensztern, Meghan Campo, Suzanne E. Dahlberg, Robert C. Doebele, Edward B. Garon, David E. Gerber, Sarah B. Goldberg, Peter S. Hammerman, Rebecca S. Heist, T...> ;Journal of Thoracic Oncology. 2015 Jan 1
21 citations
Outpatient advance care planning for patients with metastatic cancer: a pilot quality improvement initiative.
Jennifer Obel, Bruce Brockstein, Michael Marschke, Ari Robicsek, Chad Konchak, Meredith Sefa, Nicole Ziomek, Tiffany Benfield, Carrie Peterson, Cory Gustafson, Joann E...> ;Journal of Palliative Medicine. 2014 Nov 12
16 citations
Buccal spectral markers for lung cancer risk stratification
Andrew J. Radosevich, Nikhil N. Mutyal, Jeremy D. Rogers, Bradley Gould, Thomas A. Hensing, D. W. Ray, Vadim Backman, Hemant K. Roy> ;Plos One. 2014 Oct 9
14 citations
Buccal microRNA dysregulation in lung field carcinogenesis: Gender-specific implications
Ramesh K. Wali, Thomas A. Hensing, D. W. Ray, Mart Dela Cruz, Ashish K. Tiwari, Andrew J. Radosevich, Lisa Jepeal, Hiran C. Fernando, Virginia R. Litle, Marjory Charlo...> ;International Journal of Oncology. 2014 Sep 1
19 citations
Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung
Neeta Somaiah, Mary J. Fidler, Elizabeth Garrett-Mayer, Amy E. Wahlquist, Keisuke Shirai, Lela Buckingham, Thomas A. Hensing, Philip Bonomi, George R. Simon> ;Oncoscience. 2014 Aug 7
141 citations
Molecular pathways and therapeutic targets in lung cancer
Emma Shtivelman, Thomas A. Hensing, George R. Simon, Phillip A. Dennis, Gregory A. Otterson, Raphael Bueno, Ravi Salgia> ;Oncotarget. 2014 Apr 8
85 citations
A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization
Thomas A. Hensing, Apoorva Chawla, Rishi Batra, Ravi Salgia> ;Advances in Experimental Medicine and Biology. 2014 Jan 1
27 citations
Molecular biomarkers for future screening of lung cancer
Thomas A. Hensing, Ravi Salgia> ;Journal of Surgical Oncology. 2013 Oct 1
251 citations
Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
Glenwood D. Goss, Christopher J. O'Callaghan, Ian A. J. Lorimer, Ming-Sound Tsao, Gregory A. Masters, James R. Jett, Martin J. Edelman, Rogerio Lilenbaum, Hak Choy, Fa...> ;Journal of Clinical Oncology. 2013 Sep 20
147 citations
Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practic...
Mark A. Socinski, Tracey L. Evans, Scott N. Gettinger, Thomas A. Hensing, Lecia V. Sequist, Belinda Ireland, Thomas E. Stinchcombe> ;Chest. 2013 May 1
Join now to see all

Lectures

Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts...
2019 ASCO Annual Meeting - 6/1/2019